SAN FRANCISCO—A “guided missile” approach to treating metastatic, castration-resistant, taxane-refractory prostate cancer demonstrated success at the 2014 ASCO Genitourinary Cancers Symposium. Daniel Petrylak MD of Yale University Medical Center in New Haven CT discussed the clinical potential arising from his group’s study findings: anti-tumor activity and responses of PSA and circulating tumour cells arising from treatment with an immunoconjugate consisting of an antibody to prostate specific membrane antigen bonded to the microtubule-disrupting molecule monomethyl auristatin E (MMAE).
Daniel Peter Petrylak MD, Yale University Medical Center, New Haven, CT SOURCE:
Abstract No: 8
ABSTRACT TITLE: A phase II trial of prostate-specific membrane antigen antibody drug conjugate (PSMA ADC) in taxane-refractory metastatic castration-resistant prostate cancer (mCRPC).
Abstract web link: http://abstracts.asco.org/142/AbstView_142_124080.html